We use rigorous science to develop our industry-leading, evidence-based pipeline of product candidates that have the potential to transform the treatment landscape for brain health disorders.
Rethinking Brain Health with Transformational Innovation
We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in:
Generalized Anxiety Disorder (GAD)1
20M
adults in the U.S. live with GAD
Major Depressive Disorder (MDD)1
31M
adults in the U.S. live with MDD
Autism Spectrum Disorder (ASD)2
5.4M
adults in the U.S. live with ASD
The therapies we are investigating are not approved by the FDA or any other countries’ Health Authorities. This means their safety and efficacy are still being evaluated and have not been established.
- Ringeisen, H., Edlund, M. J., Guyer, H., Geiger, P., Stambaugh, L. F., Dever, J. A., Liao, D., Carr, C. M., Peytchev, A., Reed, W., McDaniel, K., & Smith, T. K. (2023). Mental and Substance Use Disorders Prevalence Study: Findings report. RTI International.
- Dietz PM, Rose CE, McArthur D, Maenner M. National and State Estimates of Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2020;50(12):4258-4266.
Learn More About Our Mission and Areas of Focus
Research & Development Pipeline
Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action
Explore MindMed’s R&D Programs to learn more about the opportunities that exist to advance novel treatments for a wide range of brain health disorders.
We have the right people working for the right reasons.
Our world-class team is advancing innovative solutions for the major unmet medical needs in brain health disorders.
Robert Barrow
Chief Executive Officer and Board Director
Miri Halperin Wernli, PhD
Executive President
Daniel Karlin, MD, MA
Chief Medical Officer
Stephanie Fagan, MS
Chief Corporate Affairs Officer
Carrie Liao, CPA
Chief Accounting Officer
Francois Lilienthal, MD, MBA
Chief Commercial Officer
Gregg Pratt, PhD
Chief Regulatory and Quality Assurance Officer
Mark Sullivan, JD
Chief Legal Officer and Corporate Secretary
Carole Abel, MBA
VP, Programs and Portfolio Office
Phong Duong, PharmD
VP, Global Market Access and Health Economics
Peter Mack, PhD
VP, Pharmaceutical Development
Rafael Muniz, MD
VP, Global Medical Affairs
Javier Muniz, MD
VP, Research and Development Strategy
Michael Seggev
VP, Global Marketing, Strategic Insights and Digital Innovation